Vicarious Surgical Inc. announced its financial results for the second quarter ended June 30, 2025, on August 12, 2025, reporting a net loss of $(13,215) thousand, an improvement from $(15,205) thousand in Q2 2024.
For the first half of 2025, the net loss was $(28,609) thousand, an 11% improvement from $(32,206) thousand in the prior year period, with loss from operations improving by 13% to $(29,266) thousand.
As of June 30, 2025, cash, cash equivalents, and short-term investments totaled $23,963 thousand, with management stating this balance is 'not sufficient to support operations for the next 12 months' from the August 12, 2025, filing date, raising 'substantial doubt about the Company’s ability to continue as a going concern.'
The company's cash runway extends only 'into the first quarter of 2026.'
Under new CEO Stephen From, the company removed the near-term target of First Clinical Use (FCU) by the end of 2025, prioritizing the completion of a fully integrated production-equivalent system due to issues like excessive electromagnetic emissions identified during testing.
The timing of FCU and the de novo FDA submission, previously late 2026, will now depend on the outcome of a 4-6 week strategic assessment initiated in August 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.